modelAntiinfectivesCombinatio
Extends from Pharmacolibrary.Drugs.ATC.S.S03AA30.
Information
| name: | AntiinfectivesCombinations | |
| ATC code: | S03AA30 | route: | topical |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | liter/hour |
| other parameters in model implementation | ||
This ATC code (S03AA30) refers to ophthalmologic antiinfective combinations, used topically in the treatment of eye infections, commonly in combination with corticosteroids or other agents. These are typically used to manage or prevent bacterial infections in ophthalmic conditions and are not systemically absorbed to a significant degree. Their use has been declining with the development of more targeted monotherapies and modern ophthalmic antimicrobial agents.
Pharmacokinetics
No published, peer-reviewed pharmacokinetic models are available for antiinfective ophthalmologic combinations with ATC S03AA30 in humans. These products are administered topically in the eye, with negligible systemic absorption and thus systemic PK parameters are not established or meaningful.
References
Aggarwal, R, et al., & Chauhan, MK (2020). Treatment and management strategies of onychomycosis. Journal de mycologie medicale 30(2) 100949–None. DOI:10.1016/j.mycmed.2020.100949 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32234349
Gupta, AK, & Studholme, C (2016). Novel investigational therapies for onychomycosis: an update. Expert opinion on investigational drugs 25(3) 297–305. DOI:10.1517/13543784.2016.1142529 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26765142
Pickert, A, & Raimer, S (2009). An evaluation of dapsone gel 5% in the treatment of acne vulgaris. Expert opinion on pharmacotherapy 10(9) 1515–1521. DOI:10.1517/14656560903002097 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19505219
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)